- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00044629
Combined Behavioral/Pharmacological Therapy for Insomnia
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Long-term insomnia is a common and significant health problem. Two main treatments, pharmacotherapy and behavioral therapy, have been used to help people with insomnia. Because both treatments have advantages and disadvantages, a combination of these treatments may be a good way to treat insomnia.
During the first 2 weeks of the study, participants keep a sleep log, wear an actigraph (a device that resembles a wristwatch and records activity to help determine when participants are asleep or awake), and complete questionnaires.
Participants are then randomly assigned to receive 6 weeks of behavioral therapy plus zolpidem tartrate (Ambien), behavioral therapy plus placebo, or behavioral therapy alone. During treatment, participants return to the clinic once a week to turn in their sleep logs, download their actigraph, and complete questionnaires.
After 6 weeks, participants enter the post-treatment phase of the study, which lasts 2 weeks and is identical to the 2-week assessment at the beginning of the study.
After the post-treatment phase, participants enter the follow-up period and are contacted at 3 months, 6 months, and 1 year to complete another 2-week assessment with sleep logs, actigraphy, and questionnaires.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
North Carolina
-
Durham, North Carolina, United States, 27710
- Duke Sleep Disorders Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- be between 21 and 75 years of age
- have a mean total nocturnal wake time of > 60 min./night
- have a history of insomnia > 6 months
- have a history of one or more poor sleep hygiene practices such as taking 3 or more naps/week, varying bed times or wake times by > 2 hrs. from day to day, or routinely lying in bed awake for periods > 30 min
Exclusion Criteria:
- pregnant women
- the terminally ill
- individuals with other medical conditions (e.g. chronic pain disorders, etc.) that compromise sleep
- individuals with major psychiatric diagnoses
- persons with hypnotic-dependent insomnia
- subjects on antidepressants or anxiolytics
- subjects with evidence of sleep apnea
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Cognitive Behavioral Therapy and Ambien
|
|
|
Placebo Comparator: Cognitive Behavioral Therapy and Placebo
|
|
|
Active Comparator: Cognitive Behavioral Therapy alone (no drug)
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start
Study Completion
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Mental Disorders
- Nervous System Diseases
- Sleep Disorders, Intrinsic
- Dyssomnias
- Sleep Wake Disorders
- Sleep Initiation and Maintenance Disorders
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Hypnotics and Sedatives
- GABA Agents
- Sleep Aids, Pharmaceutical
- GABA-A Receptor Agonists
- GABA Agonists
- Zolpidem
Other Study ID Numbers
- Pro00011850
- DSIR 83-ATAS (NIMH Program Class Code)
- R01MH062119 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sleep Initiation and Maintenance Disorders
-
Universidad de GranadaRecruiting
-
Colorado State UniversityCompleted
-
University of CyprusUniversity of Catania; Azienda ospedaliera Garibaldi CataniaRecruitingSleep QualityCyprus, Italy
-
Kirsehir Ahi Evran UniversitesiNot yet recruitingSleep Quality
-
University of CalgaryCanadian Sport Institute Alberta; PX3Recruiting
-
Universidad Autonoma de Baja CaliforniaNot yet recruiting
-
Clinique Beau SoleilNot yet recruiting
-
BELL Therapeutics Inc.Not yet recruitingInsomnia | Sleep Initiation and Maintenance DisordersSouth Korea
-
Beijing Sport UniversityNot yet recruiting
-
Beijing Tiantan HospitalInner Mongolia Autonomous Region Mental Health CenterNot yet recruiting
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
AkesoNot yet recruitingAtopic DermatitisChina
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States